

Brand Institute is Proud to Name Over 75% of Drugs Approved Worldwide

Below is a snapshot of select 2019 FDA brand name approval experience

 <p>ADAKVEO[®] crizanlizumab-tmca FOR IV INFUSION + 10 mg/mL</p>	 <p>Balversa[™] (erdafitinib) 3, 4, 5 mg tablets</p>	 <p>Beovu[®] (brolucizumab-dblj) Injection</p>
 <p>Brukinsa[™] zanubrutinib 80mg capsules</p>	 <p>DAYVIGO[™] (lemborexant) IV 5mg, 10mg tablets</p>	 <p>ENHERTU[®] fam-trastuzumab deruxtecan-nxki 20 mg/mL INJECTION FOR INTRAVENOUS USE</p>
 <p>EVENITY[™] (romosozumab-aqqg)</p>	 <p>Fetroja[®] (cefiderocol) for injection 1 gram per vial</p>	 <p>Jeuveau[™] prabotulinumtoxinA-xvfs injection</p>
<p>lbsrela tenapanor</p>	 <p>MAYZENT[®] (siponimod) tablets 0.25 mg • 2 mg</p>	 <p>PIQRAY[®] (alpelisib) tablets 50 mg • 150 mg • 200 mg</p>
 <p>RECARBRIO[™] (imipenem, cilastatin, and relebactam) for injection 1.25g</p>	 <p>ROZLYTREK[™] entrectinib 100mg 200mg capsules</p>	 <p>Turalio[™] pexidartinib 200 mg capsules</p>
 <p>Vyndaqel[®] (tafamidis)</p>	<p>XCOPRI</p>	 <p>zolgensma[®] (onasemnogene abeparvovec-xioi)</p>

BASEL +41 61-204-4575	BOSTON (781) 602-6044	CHICAGO (312) 475-9600	DALLAS (512) 369-9100	FRANKFURT +49 6196-400-966	LONDON +44 207-240-2200	LOS ANGELES (310) 830-6111	MIAMI (305) 984-6889	NEW YORK (212) 557-2100
OTTAWA (613) 482-1333	RALEIGH-DURHAM (919) 572-9311	ROCKVILLE (301) 984-1055	SAN FRANCISCO (415) 421-3200	SÃO PAULO +55 11 945-364-083	SEATTLE (206) 204-5111	SEOUL +82 6433-9555	TOKYO +81(03) 6861-7517	TORONTO (416) 622-5777